BCCA - Fraser Valley Cancer Centre

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer3 trials
• Melanoma1 trial
• Mesothelioma1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 36 trials
• Phase 22 trials
• Phase 2/31 trial

Status

• Completed5 trials
• Active, not recruiting4 trials

Lead sponsor

• Canadian Cancer Trials Group4 trials
• National Cancer Institute (NCI)2 trials
• ECOG-ACRIN Cancer Research Group1 trial
• ETOP IBCSG Partners Foundation1 trial
• Radiation Therapy Oncology Group1 trial

Running trials

• Active, not recruiting

  Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer

  NCT03793179· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

  NCT03057106· Phase 2· Canadian Cancer Trials Group· Source

• Active, not recruiting

  Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

  NCT02954874· Phase 3· National Cancer Institute (NCI)· Source

• Active, not recruiting

  Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

  NCT01368588· Phase 3· Radiation Therapy Oncology Group· Source

Closed trials

• Completed

  Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

  NCT02784171· Phase 2/3· Canadian Cancer Trials Group· Source

• Completed

  Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

  NCT02630693· Phase 2· Canadian Cancer Trials Group· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Canadian Cancer Trials Group· Source

• Completed

  Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

  NCT00066690· Phase 3· ETOP IBCSG Partners Foundation· Source

• Completed

  High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

  NCT00003641· Phase 3· ECOG-ACRIN Cancer Research Group· Source